Evidence map›Paper›PMID 39038611›Full record

ArticleBiochimica et biophysica acta. Molecular cell research2024

Reprogramming of normal fibroblasts into ovarian cancer-associated fibroblasts via non-vesicular paracrine signaling induces an activated fibroblast phenotype.

Hailey Axemaker, Simona Plesselova, Kristin Calar, Megan Jorgensen, Jared Wollman, Pilar de la Puente

Abstract read
In one paragraph

Article in Biochimica et biophysica acta. Molecular cell research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Modeling CAF-tumor interactions to overcome therapy resistance.Journal of experimental & clinical cancer research : CR · 2026
    Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hailey AxemakerCancer Biology and Immunotherapies Group, Sanford Research, Sioux Falls, SD 57104, USA.
Simona PlesselovaCancer Biology and Immunotherapies Group, Sanford Research, Sioux Falls, SD 57104, USA.
Kristin CalarCancer Biology and Immunotherapies Group, Sanford Research, Sioux Falls, SD 57104, USA.
Megan JorgensenCancer Biology and Immunotherapies Group, Sanford Research, Sioux Falls, SD 57104, USA.
Jared WollmanFlow Cytometry Core, Sanford Research, Sioux Falls, SD 57104, USA.
Pilar de la PuenteCancer Biology and Immunotherapies Group, Sanford Research, Sioux Falls, SD 57104, USA; Flow Cytometry Core, Sanford Research, Sioux Falls, SD 57104, USA; Department of Obstetrics and Gynecology, University of South Dakota Sanford School of Medicine, Sioux Falls, SD 57105, USA; Department of Surgery, University of South Dakota Sanford School of Medicine, Sioux Falls, SD 57105, USA. Electronic address: pilar.puente@sanfordhealth.org.

Funding

Yeast 2 HybridP20GM103620 · NIGMS · SANFORD RESEARCH/USD · PI ROUX, KYLE J · 2013 to 2023
$24.2M
The Impact of PD-1 Inhibition on Immune-Response to ChemoradiotherapyP20GM103548 · NIGMS · SANFORD RESEARCH/USD · PI MISKIMINS, W KEITH · 2012 to 2020
$20.8M
Tracking and Evaluation CoreU54GM128729 · NIGMS · UNIVERSITY OF NORTH DAKOTA · PI BASSON, MARC D. · 2018 to 2022
$20.3M
Role of extracellular matrix remodeling on high-grade serous ovarian carcinoma immune evasionR21CA259158 · NCI · SANFORD RESEARCH/USD · PI DE LA PUENTE, PILAR · 2022 to 2023
$423k
NCI NIH HHS R21 CA259158NIGMS NIH HHS P20 GM103548NIGMS NIH HHS P20 GM103620NIGMS NIH HHS U54 GM128729
6 · The paper itself

Abstract

Cancer-associated fibroblasts (CAFs) are key contributors to ovarian cancer (OC) progression and therapeutic resistance through dysregulation of the extracellular matrix (ECM). CAFs are a heterogenous population derived from different cell types through activation and reprogramming. Current studies rely on uncharacterized heterogenous primary CAFs or normal fibroblasts that fail to recapitulate CAF-like tumor behavior. Here, we present that conditioned media from ovarian cancer lines leads to an increase in the activated state of fibroblasts demonstrated by functional assays and up-regulation of known CAF-related genes and ECM pathways. Phenotypic and functional characterization demonstrated that the conditioned CAFs expressed a CAF-like phenotype, strengthened proliferation, secretory, contractility, and ECM remodeling properties when compared to resting normal fibroblasts, consistent with an activated fibroblast status. Moreover, conditioned CAFs significantly enhanced drug resistance and tumor progression. Critically, the conditioned CAFs resemble a transcriptional signature with involvement of ECM remodeling. The present study provides mechanistic and functional insights about the activation and reprogramming of CAFs in the ovarian tumor microenvironment mediated by non-vesicular paracrine signaling. Moreover, it provides a translational based approach to reprogram normal fibroblasts from both uterine and ovarian origin into CAFs using tumor-derived conditioned media. Using these resources, further development of therapeutics that possess potentiality and specificity towards CAF/ECM-mediated chemoresistance in OC are further warranted.

Indexed as

Cancer-Associated FibroblastsOvarian NeoplasmsParacrine CommunicationTumor MicroenvironmentAnimalsCell Line, TumorCell ProliferationCellular ReprogrammingCulture Media, ConditionedDrug Resistance, NeoplasmExtracellular MatrixFemaleFibroblastsGene Expression Regulation, NeoplasticHumansMiceCulture Media, ConditionedCancer-associated fibroblastsExtracellular matrixMatrisomeOvarian cancer

Identifiers

PMID39038611
PMCPMC11365755

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.